Orexigen Thinks Contrave On The Verge Of Approval, Again
This article was originally published in The Pink Sheet Daily
Executive Summary
The biotech once again faces an FDA approval decision for its bupropion/naltrexone obesity combo, after a long and costly cardiovascular outcomes trial has kept the drug off the market.